MENLO PARK, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third...
IRVINE, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve...
Sagard Healthcare Partners Acquires Rights to Agios’ 5% Royalty on TIBSOVO® U.S. Net SalesCAMBRIDGE, Mass. and TORONTO, Oct. 27, 2022...
NEWS RELEASE - REGULATED INFORMATION27 OCTOBER 2022, 4:00PM EDT / 22:00 CET MDxHealth Reports Q3-2022 Results IRVINE, CA, and HERSTAL,...
SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic...
STUDIO CITY, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) today announced the details of the...
NASHUA, N.H., Oct. 27, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer...
Data showcased novel compound with potential for improved anti-cancer activity over other molecular glues Salarius plans to release additional preclinical...
NEWARK, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage biotechnology company developing precision...
WILMETTE, Ill., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary...
MB-106 demonstrated 100% overall response rate in Waldenstrom macroglobulinemia Data to be presented by Fred Hutch’s Dr. Mazyar Shadman WORCESTER,...
– Two Academic Powerhouses form Institut Pasteur-UCSF QBI Center of Excellence in Emerging Diseases with Planned Operations/Locations in San Francisco...
CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery...
BOCA RATON, Fla., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in...
COVALENT-101 now includes patients with relapsed/refractory (R/R) CLLBMF-219 is the first menin inhibitor in the clinic for CLLPreclinical data presented...
Jared Weiss, MD, Lead Investigator for the VERSATILE-002 clinical trial combining PDS0101 and KEYTRUDA®, presents interim data from the study...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM AUSTRALIA, CANADA,...
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Oct. 27, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM;...
CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on...
SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing...